The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options
Open Access
- 31 March 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (3) , e0152347
Abstract
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be used to develop prognostic indicators and biomarkers of disease evolution and therapeutic response. The Swiss MS Cohort (SMSC) is a prospective observational study performed across seven Swiss MS centers including patients with MS, clinically isolated syndrome (CIS), radiologically isolated syndrome or neuromyelitis optica. Neurological and radiological assessments and biological samples are collected every 6–12 months. We recruited 872 patients (clinically isolated syndrome [CIS] 5.5%, relapsing-remitting MS [RRMS] 85.8%, primary progressive MS [PPMS] 3.5%, secondary progressive MS [SPMS] 5.2%) between June 2012 and July 2015. We performed 2,286 visits (median follow-up 398 days) and collected 2,274 serum, plasma and blood samples, 152 cerebrospinal fluid samples and 1,276 brain MRI scans. 158 relapses occurred and expanded disability status scale (EDSS) scores increased in PPMS, SPMS and RRMS patients experiencing relapses. Most RRMS patients were treated with fingolimod (33.4%), natalizumab (24.5%) or injectable DMDs (13.6%). The SMSC will provide relevant information regarding DMDs efficacy and safety and will serve as a comprehensive infrastructure available for nested research projects.Keywords
This publication has 34 references indexed in Scilit:
- Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosisNature Reviews Neurology, 2014
- Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment StrategiesMayo Clinic Proceedings, 2014
- Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosisNature Genetics, 2013
- The costs of disorders of the brain in Switzerland: an update from the European Brain Council Study for 2010Swiss Medical Weekly, 2012
- GBD 2010: design, definitions, and metricsThe Lancet, 2012
- Multiple sclerosis: risk factors, prodromes, and potential causal pathwaysThe Lancet Neurology, 2010
- The changing demographic pattern of multiple sclerosis epidemiologyThe Lancet Neurology, 2010
- Multiple sclerosis immunologyNeurology, 2010
- Multiple sclerosisThe Lancet, 2008
- The Immunopathology of Multiple Sclerosis: An OverviewBrain Pathology, 2007